Clinical Trial Application (CTA)
What a definition is not
A definition is SPEQ’s plain-language decode of how a term is used in practice, cited to the documents that define it. It is a practitioner reference, not legal or regulatory advice, it does not replace the definition in the source, and where a regulator’s wording differs the regulator’s wording governs.
The regulatory submission a sponsor files with a national or regional competent authority to obtain authorization to conduct a clinical trial, distinct from a US Investigational New Drug application though serving the equivalent gatekeeping function. Content typically includes the protocol, Investigator’s Brochure, manufacturing and quality information, and ethics committee documentation.
Terminology and process vary by region: “Clinical Trial Application” is the term used in the European Union and several other jurisdictions, while the United States uses the Investigational New Drug application — the two serve the same regulatory purpose of authorizing human study of an investigational product but are not identical filings.
In the EU, a CTA is submitted once through the Clinical Trials Information System (CTIS) under the Clinical Trials Regulation, covering all participating member states through a single, coordinated assessment rather than separate national filings.
Because required content, review timelines, and the scope of what needs local authorization differ meaningfully by region, sponsors running multi-region trials must confirm the applicable rules in each jurisdiction rather than assume equivalence with an IND.
- —Regional equivalent of the US IND, filed with the competent authority before a trial may start.
- —In the EU, filed once through the Clinical Trials Information System (CTIS) for all participating member states under the CTR.
- —Requires the protocol, current Investigator’s Brochure, quality and manufacturing data, and supporting ethics documentation.
- —Authorization timelines and required content vary meaningfully by region and must be confirmed locally.
EU Regulation 536/2014 (Clinical Trials Regulation); ICH E6(R3) GCP
Frequently asked questions
What is Clinical Trial Application (CTA)?
The regulatory submission a sponsor files with a national or regional competent authority to obtain authorization to conduct a clinical trial, distinct from a US Investigational New Drug application though serving the equivalent gatekeeping function. Content typically includes the protocol, Investigator’s Brochure, manufacturing and quality information, and ethics committee documentation.
Which regulations cover Clinical Trial Application (CTA)?
EU Regulation 536/2014 (Clinical Trials Regulation); ICH E6(R3) GCP